CJC-1295 with DAC Side Effects

Reported CJC-1295 with DAC side effects

Expected / benign Injection-site reaction — redness, slight swelling, itching at the weekly injection Facial flushing / warmth post-injection, sometimes lasting hours (longer than with MOD-GRF 1-29) Vivid dreams — very common in first weeks Mild nausea at higher doses initially Hunger increase — less than ghrelin-receptor agonists Common (dose-related) Water retention / peripheral edema — more prominent than with MOD-GRF 1-29 due to sustained GH elevation Finger / wrist stiffness, paresthesias — carpal tunnel symptoms, dose-responsive Fatigue or lethargy during first 1-2 weeks — resolves as axis stabilizes Elevated fasting glucose — GH is counter-regulatory to insulin; more common with DAC than MOD-GRF 1-29 Mild insulin resistance — reflected in HOMA-IR rise on fasting insulin + glucose Less common but clinically important Significant carpal tunnel syndrome — may require dose reduction or discontinuation Joint pain / arthralgia — knees, hips, fingers Headache — persistent, usually resolves with dose reduction Sleep changes — ironically, sustained GH can disrupt the natural GH pulse pattern and worsen sleep architecture Dose-related serious Glucose intolerance / overt type 2 diabetes — sustained GH elevation is a known cause; particular risk in predisposed individuals Acromegaly-like features — theoretical at chronic high-dose use; not documented at therapeutic doses Peripheral neuropathy from sustained edema / compression Potential pro-tumorigenic effect — sustained high IGF-1 epidemiologically associated with increased cancer risk (Renehan et al., 2004) Absolute contraindications Active malignancy (any type) History of cancer within 5 years Diabetic retinopathy Pregnancy and lactation Children with open growth plates Critical illness (ICU care) — GH increased mortality in this population ([Takala 1999]) Severe uncontrolled type 2 diabetes Relative contraindications Type 2 diabetes (well-controlled) Obstructive sleep apnea Intracranial pathology Severe hypothyroidism Family history of acromegaly Particular safety concerns specific to DAC variant (vs non-DAC) Sustained IGF-1 elevation: greater cancer-association concern No "off" period in receptor exposure: higher desensitization risk Limited ability to adjust dose mid-week if side effects occur (half-life is long) Cannot be stopped rapidly in emergency (washout 2-3 weeks to baseline) Lab monitoring essential Baseline: IGF-1, IGFBP-3, fasting glucose, HbA1c, CBC, CMP Follow-up: IGF-1 at 4 weeks and 12 weeks; fasting glucose and HbA1c quarterly Target: IGF-1 at upper-normal for age, NOT supraphysiologic

When to continue, reduce, or stop CJC-1295 with DAC

CJC-1295 with DAC contraindications

Absolute contraindications Active malignancy of any type — sustained IGF-1 elevation is a stronger pro-tumorigenic concern than with pulsatile MOD-GRF 1-29 History of cancer within 5 years — relative; discuss with oncologist Diabetic retinopathy (active or history) Pregnancy and lactation Children with open growth plates Critical illness requiring ICU care — Takala 1999 signal of increased mortality with sustained GH Severe uncontrolled type 2 diabetes (HbA1c >8) — sustained GH worsens glucose Relative contraindications Controlled type 2 diabetes — use non-DAC form preferentially Obstructive sleep apnea Severe hypothyroidism Intracranial pathology Family history of acromegaly or pituitary adenoma Drug interactions Glucocorticoids — may blunt response; minimize Somatostatin analogs — direct GH suppression; incompatible Insulin / insulin secretagogues — counter-regulatory; monitor glucose Oral estrogens (high-dose) — blunt hepatic IGF-1 response Chemotherapy agents — avoid concurrent use Surgery considerations Hold 2-3 weeks before elective major surgery (due to longer washout) Disclose to all clinicians, especially oncology, endocrinology, ophthalmology Washout from DAC is 3-4 weeks due to ~8-day half-life plus albumin half-life WADA prohibition GH-releasing peptides prohibited at all times for competitive athletes Urine testing can detect GH-axis manipulation via GH isoform ratios and IGF-1 measurements Disclosure obligations All clinicians Insurance applications (material in some jurisdictions) Workers' compensation / disability evaluations Cannot be rapidly reversed Because of the 8-day half-life and 3-4 week washout, CJC-1295 with DAC cannot be rapidly discontinued in response to an acute side effect or contraindication change. Users and clinicians must be prepared for this.

Why vendor quality drives CJC-1295 with DAC side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

CJC-1295 with DAC side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .